Analgesic Efficacy of Maxigesic in Breast Cancer Surgery
The present study aims to find a perioperative analgesic method that provides sufficient analgesia while reducing immune compromise in cancer surgery. This study is to investigate the analgesic effect and safety of Maxigesic inj. (a combination of acetaminophen 1000 mg and ibuprofen 300 mg), which is added to opioid-based IV-PCA in patients undergoing breast cancer surgery.
Breast Cancer
DRUG: Maxigesic|DRUG: 0.9% saline solution
Analgesic effect of Maxigesic, Postoperative pain intensity is assessed with NRS: numerical rating scales (0 = no pain âˆ¼ 10 = worst pain)., postoperative 30 minutes/ 6 hours/ 24 hours/ 48 hours
Incidence of Adverse reactions (Safety), Adverse reactions related to NSAIDs: headache, dizziness, nausea, vomiting, itching, drowsiness, abdominal pain, constipation, gastrointestinal bleeding, hypotension., postoperative 30 minutes/ 6 hours/ 24 hours/ 48 hours
The present study aims to find a perioperative analgesic method that provides sufficient analgesia while reducing immune compromise in cancer surgery. This study is to investigate the analgesic effect and safety of Maxigesic inj. (a combination of acetaminophen 1000 mg and ibuprofen 300 mg), which is added to opioid-based IV-PCA in patients undergoing breast cancer surgery.